Cibinqo (abrocitinib) is a medication that is prescribed to treat moderate to severe atopic dermatitis in adults and pediatric patients 12 years and older. Cibinqo is a tablet that is taken orally once daily, with or without food.

Uses:

Cibinqo (abrocitinib) is used to treat moderate to severe atopic dermatitis in adults and children aged 12 years and older who have not responded well to, or cannot use, topical treatments for atopic dermatitis.

HOW TO USE:

Cibinqo should be taken orally once daily, with or without food. The recommended starting dose for adults is 200 mg and 100 mg for patients who weigh less than 60 kg. The recommended starting dose for pediatric patients aged 12 to 17 years is based on weight, with a maximum dose of 200 mg per day.

Dosage:

Cibinqo dosage should be based on the patient’s body weight and age. For adults, the recommended dose is 200 mg daily. For adolescents aged 12-17 years old who weigh less than 40 kg, a dose of 100 mg should be administered orally once daily; For patients who weigh 40 kg or more, a dose of 200 mg should be administered orally once daily.

Mechanism of Action:

Cibinqo is a Janus kinase (JAK) inhibitor that works by blocking the activity of certain enzymes in the body that are involved in the immune response. This helps reduce inflammation and other symptoms associated with atopic dermatitis.

Storage Conditions:

Cibinqo should be stored at room temperature away from heat and moisture.

Precautions:

• Cibinqo may cause an increased risk of serious infections, including tuberculosis (TB) and herpes zoster. Patients should inform their healthcare provider of any signs or symptoms of infection, such as fever, chills, cough, or unusual rash, while taking Cibinqo.
• The medication can also cause an increased risk of malignancies, including lymphoma and skin cancer. Patients should avoid prolonged exposure to sunlight and seek medical attention for any suspicious or new skin lesions or moles.
• Cibinqo can cause serious allergic reactions. Patients should seek emergency medical attention if they experience symptoms of an allergic reaction, such as difficulty breathing, swelling of the face, lips, tongue, or throat, or a severe rash.

Interactions:

• Cibinqo may interact with other medications that affect the immune system, such as immunosuppressive medications, increasing the risk of infections.
• Patients should inform their healthcare provider of all medications they are taking, including prescription and over-the-counter medications, nutritional supplements, and herbal remedies, before starting treatment with Cibinqo.

Contraindications:

• Cibinqo is contraindicated in patients who are allergic to abrocitinib or any of its components.

Side Effects:

The most common side effects of Cibinqo include nausea, headache, and upper respiratory tract infection. Other possible side effects may include diarrhea, vomiting, abdominal pain, and elevated liver enzymes. Serious side effects associated with Cibinqo include infections, malignancies, and anaphylaxis. Patients should inform their healthcare provider if they experience any unusual symptoms while taking Cibinqo.

Overdose:

In case of an overdose, patients should seek emergency medical attention immediately.

In conclusion, Cibinqo (abrocitinib) is a medication that is prescribed to treat moderate to severe atopic dermatitis in adults and pediatric patients 12 years and older. The recommended dose is based on the patient’s body weight and age. Cibinqo works by blocking the activity of certain enzymes in the body that are involved in the immune response, which helps reduce inflammation and other symptoms associated with atopic dermatitis. The medication can cause an increased risk of serious infections, malignancies, and allergic reactions, and it should not be used in patients who are allergic to abrocitinib or any of its components. Cibinqo should be stored at room temperature away from heat and moisture, and patients should inform their healthcare providers of all medications they are taking before starting treatment with Cibinqo.